Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: A systematic review

Reviews in Medical Virology

Volumn 24, Issue 6, 2014, Pages 420-433

  Hamilton, Stuart T ^a,b   van Zuylen, Wendy ^a,c   Shand, Antonia ^d   Scott, Gillian M ^c   Naing, Zin ^a,c   Hall, Beverley ^a   Craig, Maria E ^a,b,e   Rawlinson, William D ^a,b,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; HYPERIMMUNE GLOBULIN; VALACICLOVIR; VALGANCICLOVIR;

BEHAVIOR CHANGE; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FETAL MORBIDITY; HUMAN; INFECTION PREVENTION; INTRAUTERINE INFECTION; META ANALYSIS; NEWBORN INFECTION; NEWBORN MORBIDITY; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONAL HYGIENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIMARY PREVENTION; REHABILITATION; REVIEW; SECONDARY PREVENTION; SEROCONVERSION; SYSTEMATIC REVIEW; ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; FEMALE; MALE; NEWBORN; PHYSIOLOGY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84925674732     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1814     Document Type: Review

References (106)

1. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Reviews in Medical Virology 2007; 17: 355-363. DOI: 10.1002/rmv.544
2. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007; 17: 253-276. DOI: 10.1002/rmv.535
3. McMullan BJ, Palasanthiran P, Jones CA, et al. Congenital cytomegalovirus-time to diagnosis, management and clinical sequelae in Australia: opportunities for earlier identification. Medical Journal of Australia 2011; 194: 625-629.
4. Munro SC, Hall B, Whybin LR, et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. Journal of Clinical Microbiology 2005; 43: 4713-4718. 43/9/4713 [pii] DOI: 10.1128/JCM.43.9.4713-4718.2005
5. Beck S, Wojdyla D, Say L, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bulletin of the World Health Organization 2010; 88: 31-38. DOI: 10.2471/BLT.08.062554
6. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatric Infectious Disease Journal 1992; 11: 93-99.
7. Nuovo GJ, MacConnell P, Gallery F. Analysis of nonspecific DNA synthesis during in situ PCR and solution-phase PCR. PCR Methods and Applications 1994; 4: 89-96.
8. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clinical Microbiology and Infection 2011; 17: 1285-1293. DOI: 10.1111/j.1469-0691.2011.03564.x
9. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clinical Infectious Diseases 2011; 52: e11-e13. DOI: 10.1093/cid/ciq085
10. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, Vossen AC. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Reviews in Medical Virology 2013; 23: 241-249. DOI: 10.1002/rmv.1744
11. Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. Journal of Infectious Diseases 2011; 203: 1526-1533. jir121 [pii] DOI: 10.1093/infdis/jir121
12. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Reviews in Medical Virology 2010; 20: 202-213. DOI: 10.1002/rmv.655
13. Stagno S, Pass RF, Dworsky ME, Alford CA. Congenital and perinatal cytomegalovirus infections. Seminars in Perinatology 1983; 7: 31-42.
14. Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrobial Agents and Chemotherapy 2007; 51: 89-94. AAC.00633-06 [pii] DOI: 10.1128/AAC.00633-06
15. Chan G, Guilbert LJ. Enhanced monocyte binding to human cytomegalovirus-infected syncytiotrophoblast results in increased apoptosis via the release of tumour necrosis factor alpha. Journal of Pathology 2005; 207: 462-470. DOI: 10.1002/path.1849
16. Hamilton ST, Scott G, Naing Z, et al. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLoS One 2012; 7: e52899. PONE-D-12-21445 [pii] DOI: 10.1371/journal.pone.0052899
17. Maidji E, Nigro G, Tabata T, et al. Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. American Journal of Pathology 2010; 177: 1298-1310. ajpath.2010.091210 [pii] DOI: 10.2353/ajpath.2010.091210
18. Tabata T, Kawakatsu H, Maidji E, et al. Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor-beta1 and increased collagen production. American Journal of Pathology 2008; 172: 1127-1140. ajpath.2008.070448 [pii] DOI: 10.2353/ajpath.2008.070448
19. Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. Journal of Virology 2004; 78: 2831-2840.
20. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clinical Infectious Diseases 2004; 39: 233-239. CID32962 [pii] DOI: 10.1086/421999
21. Rahav G. Congenital cytomegalovirus infection-a question of screening. The Israel Medical Association Journal 2007; 9: 392-394.
22. Forsgren M. Prevention of congenital and perinatal infections. Euro Surveillance 2009; 14: 2-4.
23. Adler SP. Screening for cytomegalovirus during pregnancy. Infectious Diseases in Obstetrics and Gynecology 2011; 2011: 1-9. DOI: 10.1155/2011/942937
24. Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy and Childbirth 2013; 13: 96. 1471-2393-13-96 [pii] DOI: 10.1186/1471-2393-13-96
25. Adler SP. The molecular epidemiology of cytomegalovirus transmission among children attending a day care center. Journal of Infectious Diseases 1985; 152: 760-768.
26. Hutto C, Ricks R, Garvie M, Pass RF. Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatric Infectious Disease 1985; 4: 149-152.
27. Pass RF, August AM, Dworsky M, Reynolds DW. Cytomegalovirus infection in day-care center. New England Journal of Medicine 1982; 307: 477-479. DOI: 10.1056/NEJM198208193070804
28. Pass RF, Little EA, Stagno S, Britt WJ, Alford CA. Young children as a probable source of maternal and congenital cytomegalovirus infection. New England Journal of Medicine 1987; 316: 1366-1370. DOI: 10.1056/NEJM198705283162203
29. Marshall BC, Adler SP. The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care. American Journal of Obstetrics and Gynecology 2009; 200: 163 e161-163 e165. S0002-9378(08)00966-6 [pii] DOI: 10.1016/j.ajog.2008.08.037
30. Noyola DE, Valdez-Lopez BH, Hernandez-Salinas AE, et al. Cytomegalovirus excretion in children attending day-care centers. Archives of Medical Research 2005; 36: 590-593. S0188-4409(05)00211-0 [pii] DOI: 10.1016/j.arcmed.2005.03.045
31. Ross DS, Victor M, Sumartojo E, Cannon MJ. Women's knowledge of congenital cytomegalovirus: results from the 2005 HealthStyles™ survey. Journal of Women's Health 2008; 17: 849-858. DOI: 10.1089/jwh.2007.0523
32. Jeon J, Victor M, Adler S, et al. Knowledge and awareness of congenital cytomegalovirus among women. Infectious Diseases in Obstetrics and Gynecology 2006; 2006: 1-7. DOI: 10.1155/IDOG/2006/80383
33. Korver AM, de Vries JJ, de Jong JW, Dekker FW, Vossen AC, Oudesluys-Murphy AM. Awareness of congenital cytomegalovirus among doctors in the Netherlands. Journal of Clinical Virology 2009; 46(Suppl 4): S11-S15. DOI: 10.1016/j.jcv.2009.09.006
34. Cordier AG, Guitton S, Vauloup-Fellous C, Grangeot-Keros L, Benachi A, Picone O. Awareness and knowledge of congenital cytomegalovirus infection among health care providers in France. Journal of Clinical Virology 2012; 55: 158-163. DOI: 10.1016/j.jcv.2012.06.022
35. Cannon MJ, Westbrook K, Levis D, Schleiss MR, Thackeray R, Pass RF. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Preventive Medicine 2012; 54: 351-357. DOI: 10.1016/j.ypmed.2012.03.009
36. Cordier AG, Guitton S, Vauloup-Fellous C, et al. Awareness of cytomegalovirus infection among pregnant women in France. Journal of Clinical Virology 2012; 53: 332-337. DOI: 10.1016/j.jcv.2011.12.031
37. Pereboom MT, Mannien J, Spelten ER, Schellevis FG, Hutton EK. Observational study to assess pregnant women's knowledge and behaviour to prevent toxoplasmosis, listeriosis and cytomegalovirus. BMC Pregnancy and Childbirth 2013; 13: 98. 1471-2393-13-98 [pii] DOI: 10.1186/1471-2393-13-98
38. Knowledge and practices of obstetricians and gynecologists regarding cytomegalovirus infection during pregnancy-United States, 2007. MMWR. Morbidity and Mortality Weekly Report 2008; 57: 65-68.
39. Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. New England Journal of Medicine 2014; 370: 1316-1326. DOI: 10.1056/NEJMoa1310214
40. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653 [25 August 2014].
41. Wagner N, Kagan KO, Haen S, et al. Effective management and intrauterine treatment of congenital cytomegalovirus infection: review article and case series. Journal of Maternal-Fetal and Neonatal Medicine 2014; 27: 209-214. DOI: 10.3109/14767058.2013.806899
42. Berger A, Reitter A, Harter PN, et al. Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases. Journal of Clinical Virology 2011; 51: 285-288. DOI: 10.1016/j.jcv.2011.05.007
43. Simioni C, Sanchez Oliveira Rde C, Moscovi T, D' Agostini Deutsch A, Cordioli E, Santos E. Twin pregnancy and congenital cytomegalovirus: case report and review. Journal of Maternal-Fetal and Neonatal Medicine 2013; 26: 622-624. DOI: 10.3109/14767058.2012.745503
44. Moise KJ, Wolfe H. Treatment of second trimester fetal cytomegalovirus infection with maternal hyperimmune globulin. Prenatal Diagnosis 2008; 28: 264-265. DOI: 10.1002/pd.1954
45. Moxley K, Knudtson EJ. Resolution of hydrops secondary to cytomegalovirus after maternal and fetal treatment with human cytomegalovirus hyperimmune globulin. Obstetrics & Gynecology 2008; 111: 524-526. DOI: 10.1097/01.AOG.0000281669.19021.0f
46. Negishi H, Yamada H, Hirayama E, et al. Intraperitoneal administration of cytomegalovirus hyperimmunoglobulin to the cytomegalovirus-infected fetus. Journal of Perinatology 1998; 18: 466-469.
47. Oschman A, Murthy V, Kollipara R, Kenneth Lord R, Oluola O. Intravitreal ganciclovir for neonatal cytomegalovirus-associated retinitis: a case report. Journal of Perinatology 2013; 33: 329-331. DOI: 10.1038/jp.2012.139
48. Lalezary M, Recchia FM, Kim SJ. Treatment of congenital cytomegalovirus retinitis with intravitreous ganciclovir. Archives of Ophthalmology 2012; 130: 525-527. DOI: 10.1001/archophthalmol.2011.1615
49. Okulu E, Akin IM, Atasay B, Ciftci E, Arsan S, Turmen T. Severe postnatal cytomegalovirus infection with multisystem involvement in an extremely low birth weight infant. Journal of Perinatology 2012; 32: 72-74. DOI: 10.1038/jp.2011.58
50. Dallar Y, Tiras U, Catakli T, et al. Life-threatening intracranial bleeding in a newborn with congenital cytomegalovirus infection: late-onset neonatal hemorrhagic disease. Pediatric Hematology and Oncology 2011; 28: 78-82. DOI: 10.3109/08880018.2010.513032
51. Poyrazoglu HM, Dursun I, Bastug F, Gunduz Z, Akyildiz BN, Tulpar S. Cytomegalovirus infection and haemophagocytosis in a patient with congenital nephrotic syndrome. Pediatric Nephrology 2009; 24: 2257-2259. DOI: 10.1007/s00467-009-1243-5
52. Besbas N, Bayrakci US, Kale G, et al. Cytomegalovirus-related congenital nephrotic syndrome with diffuse mesangial sclerosis. Pediatric Nephrology 2006; 21: 740-742. DOI: 10.1007/s00467-006-0051-4
53. Puliyanda DP, Silverman NS, Lehman D, et al. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transplant Infectious Disease 2005; 7: 71-74. DOI: 10.1111/j.1399-3062.2005.00089.x
54. Sampath V, Narendran V, Donovan EF, Stanek J, Schleiss MR. Nonimmune hydrops fetalis and fulminant fatal disease due to congenital cytomegalovirus infection in a premature infant. Journal of Perinatology 2005; 25: 608-611. DOI: 10.1038/sj.jp.7211357
55. Voudris K, Vagiakou EA, Mastroyianni S, Dimitriou Y, Skardoutsou A. Infantile spasms in an infant with cytomegalovirus infection treated with ganciclovir. Journal of Child Neurology 2004; 19: 50-53.
56. Weng YH, Chu SM, Lien RI, Chou YH, Lin TY. Clinical experience with ganciclovir and anti-cytomegalovirus immunoglobulin treatment for a severe case of congenital cytomegalovirus infection. Chang Gung Medical Journal 2003; 26: 128-132.
57. Barampouti F, Rajan M, Aclimandos W. Should active CMV retinitis in non-immunocompromised newborn babies be treated? British Journal of Ophthalmology 2002; 86: 248-249.
58. Reiterer F, Dornbusch HJ, Urlesberger B, et al. Cytomegalovirus associated neonatal pneumonia and Wilson-Mikity syndrome: a causal relationship? European Respiratory Journal 1999; 13: 460-462.
59. Fox LM, Gerber MA, Penix L, Ricci A Jr, Hyams JS. Intractable diarrhea from cytomegalovirus enterocolitis in an immunocompetent infant. Pediatrics 1999; 103: E10.
60. Stronati M, Revello MG, Cerbo RM, Furione M, Rondini G, Gerna G. Ganciclovir therapy of congenital human cytomegalovirus hepatitis. Acta Paediatrica 1995; 84: 340-341.
61. Staunton BH, Crabbe D, Cullinane C, Smith D. Congenital cytomegalovirus infection associated with development of neonatal emphysematous lung disease. BMJ Case Report 2012; 2012. DOI: 10.1136/bcr.02.2012.5737
62. Irizarry K, Honigbaum S, Demmler-Harrison G, Rippel S, Wilsey M Jr. Successful treatment with oral valganciclovir of primary CMV enterocolitis in a congenitally infected infant. Fetal and Pediatric Pathology 2011; 30: 437-441. DOI: 10.3109/15513815.2011.587501
63. Stronati M, Garofoli F, Angelini M, Licari A, Manzoni P, Lombardi G. Valganciclovir treatment in a 6-month-old infant with asymptomatic congenital cytomegalovirus infection and late hearing loss. Pediatric Infectious Disease Journal 2011; 30: 1124-1125. DOI: 10.1097/INF.0b013e3182293439
64. Imamura T, Suzutani T, Ogawa H, et al. Oral valganciclovir treatment for congenital cytomegalovirus infection. Pediatrics International 2011; 53: 249-252. DOI: 10.1111/j.1442-200X.2010.03217.x
65. Kashiwagi Y, Kawashima H, Nakajima J, et al. Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection. Journal of Infection and Chemotherapy 2011; 17: 538-540. DOI: 10.1007/s10156-010-0204-z
66. Choi KY, Sharon B, Balfour HH Jr, Belani K, Pozos TC, Schleiss MR. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. Journal of Clinical Virology 2013; 57: 356-360. DOI: 10.1016/j.jcv.2013.04.004
67. El-Sayed MF, Goldfarb DM, Fulford M, Pernica JM. Severe late-onset multisystem cytomegalovirus infection in a premature neonate previously treated for congenital infection. BMC Pediatrics 2013; 13: 142. DOI: 10.1186/1471-2431-13-142
68. Piersigilli F, Catena G, De Gasperis MR, Lozzi S, Auriti C. Active retinitis in an infant with postnatally acquired cytomegalovirus infection. Journal of Perinatology 2012; 32: 559-562. DOI: 10.1038/jp.2011.142
69. Hayakawa J, Kawakami Y, Takeda S, et al. A neonate with reduced cytomegalovirus DNA copy number and marked improvement of hearing in the treatment of congenital cytomegalovirus infection. Journal of Nippon Medical School 2012; 79: 471-477.
70. Yilmaz Ciftdogan D, Vardar F. Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection. Journal of Tropical Pediatrics 2011; 57: 132-134. DOI: 10.1093/tropej/fmq050
71. Shoji K, Ito N, Ito Y, et al. Is a 6-week course of ganciclovir therapy effective for chorioretinitis in infants with congenital cytomegalovirus infection? Journal of Pediatrics 2010; 157: 331-333. DOI: 10.1016/j.jpeds.2010.02.020
72. Muller A, Eis-Hubinger AM, Brandhorst G, Heep A, Bartmann P, Franz AR. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. Journal of Perinatology 2008; 28: 74-76. DOI: 10.1038/sj.jp.7211854
73. Schulzke S, Buhrer C. Valganciclovir for treatment of congenital cytomegalovirus infection. European Journal of Pediatrics 2006; 165: 575-576. DOI: 10.1007/s00431-006-0109-0
74. Meine Jansen CF, Toet MC, Rademaker CM, Ververs TF, Gerards LJ, van Loon AM. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. Journal of Perinatal Medicine 2005; 33: 364-366. DOI: 10.1515/jpm.2005.065
75. Campanini G, Zavattoni M, Cristina E, Gazzolo D, Stronati M, Baldanti F. Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection. Journal of Clinical Virology 2012; 54: 86-88. DOI: 10.1016/j.jcv.2012.01.020
76. Nigro G, Sali E, Anceschi MM, et al. Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites. Journal of Maternal-Fetal and Neonatal Medicine 2004; 15: 325-329. DOI: 10.1080/14767050410001701349
77. Tawse KL, Baumal CR. Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant. Journal of American Association for Pediatric Ophthalmology and Strabismus 2014; 18: 78-80. DOI: 10.1016/j.jaapos.2013.09.015
78. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. New England Journal of Medicine 2009; 360: 1191-1199. DOI: 10.1056/NEJMoa0804749
79. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatric Infectious Disease Journal 1996; 15: 240-246.
80. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. Journal of Pediatrics 2004; 145: 485-491. S0022-3476(04)00454-8 [pii] DOI: 10.1016/j.jpeds.2004.05.041
81. Vauloup-Fellous C, Picone O, Cordier AG, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. Journal of Clinical Virology 2009; 46(Suppl 4): S49-S53. S1386-6532(09)00419-3 [pii] DOI: 10.1016/j.jcv.2009.09.003
82. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. New England Journal of Medicine 2005; 353: 1350-1362. DOI: 10.1056/NEJMoa043337
83. Nigro G, Capretti I, Manganello AM, Best AM, Adler SP. Primary maternal cytomegalovirus infections during pregnancy: association of CMV hyperimmune globulin with gestational age at birth and birth weight. Journal of Maternal-Fetal and Neonatal Medicine 2014. DOI: 10.3109/14767058.2014.907265
84. Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy-a case-control study of the outcome in children. Journal of Infectious Diseases 2012; 205: 215-227.
85. Buxmann H, Stackelberg OM, Schlosser RL, et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. Journal of Perinatal Medicine 2012; 40: 439-446. DOI: 10.1515/jpm-2011-0257
86. Bodeus M, Kabamba-Mukadi B, Zech F, Hubinont C, Bernard P, Goubau P. Human cytomegalovirus in utero transmission: follow-up of 524 maternal seroconversions. Journal of Clinical Virology 2010; 47: 201-202. S1386-6532(09)00550-2 [pii] DOI: 10.1016/j.jcv.2009.11.009
87. Enders G, Daiminger A, Bader U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. Journal of Clinical Virology 2011; 52: 244-246. S1386-6532(11)00280-0 [pii] DOI: 10.1016/j.jcv.2011.07.005
88. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1year of age. Clinical Infectious Diseases 2012; 55: 497-503. cis423 [pii] DOI: 10.1093/cid/cis423
89. The Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study G. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. Journal of Reproductive Immunology 2012; 95: 73-79.
90. Nigro G, Adler SP, Gatta E, et al. Fetal hyperechogenic bowel may indicate congenital cytomegalovirus disease responsive to immunoglobulin therapy. Journal of Maternal-Fetal and Neonatal Medicine 2012; 25: 2202-2205. DOI: 10.3109/14767058.2012.684111
91. Jacquemard F, Yamamoto M, Costa JM, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 2007; 114: 1113-1121. DOI: 10.1111/j.1471-0528.2007.01308.x
92. Roxby AC, Atkinson C, Asbjornsdottir K, et al. Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women. PLoS One 2014; 9: e87855. DOI: 10.1371/journal.pone.0087855
93. Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. Journal of Pediatrics 1994; 124: 318-322.
94. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Journal of Infectious Diseases 1997; 175: 1080-1086.
95. Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatric Infectious Disease Journal 2003; 22: 504-509. DOI: 10.1097/01.inf.0000069767.43169.2d
96. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. Journal of Pediatrics 2003; 143: 16-25.
97. Tanaka-Kitajima N, Sugaya N, Futatani T, et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatric Infectious Disease Journal 2005; 24: 782-785.
98. Lackner A, Acham A, Alborno T, et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10year follow up. Journal of Laryngology and Otology 2009; 123: 391-396. DOI: 10.1017/s0022215108003162
99. Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. European Journal of Clinical Microbiology and Infectious Diseases 2009; 28: 1465-1470. DOI: 10.1007/s10096-009-0806-5
100. del Rosal T, Baquero-Artigao F, Blazquez D, et al. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period. Journal of Clinical Virology 2012; 55: 72-74. DOI: 10.1016/j.jcv.2012.06.001
101. Harvey J, Dennis CL. Hygiene interventions for prevention of cytomegalovirus infection among childbearing women: systematic review. Journal of Advanced Nursing 2008; 63: 440-450. DOI: 10.1111/j.1365-2648.2008.04726.x
102. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions, 2011. http://www.cochrane-handbook.org/ [25 August 2014].
103. Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Medical Journal of Australia 2002; 177: 256-257.
104. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New England Journal of Medicine 1978; 299: 690-694. DOI: 10.1056/NEJM197809282991304
105. Preventing Congenital CMV Infection. http://www.cdc.gov/cmv/prevention.html [26 May 2014].
106. Kimberlin DW, Jester P, Sanchez PJ, et al. Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study. In IDWeek, San Francisco, California, October 2-6, 2013.